AU2001273310B2 - A core formulation - Google Patents

A core formulation Download PDF

Info

Publication number
AU2001273310B2
AU2001273310B2 AU2001273310A AU2001273310A AU2001273310B2 AU 2001273310 B2 AU2001273310 B2 AU 2001273310B2 AU 2001273310 A AU2001273310 A AU 2001273310A AU 2001273310 A AU2001273310 A AU 2001273310A AU 2001273310 B2 AU2001273310 B2 AU 2001273310B2
Authority
AU
Australia
Prior art keywords
formulation
patient
core
metformin
alpha
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
AU2001273310A
Other languages
English (en)
Other versions
AU2001273310A1 (en
Inventor
Akwete L. Adjei
Anthony J. Cutie
Yaping Zhu
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Kos Life Sciences Inc
Original Assignee
Kos Life Sciences Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Kos Life Sciences Inc filed Critical Kos Life Sciences Inc
Publication of AU2001273310A1 publication Critical patent/AU2001273310A1/en
Application granted granted Critical
Publication of AU2001273310B2 publication Critical patent/AU2001273310B2/en
Assigned to KOS LIFE SCIENCES, INC. reassignment KOS LIFE SCIENCES, INC. Request for Assignment Assignors: AEROPHARM TECHNOLOGY, INC.
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/155—Amidines (), e.g. guanidine (H2N—C(=NH)—NH2), isourea (N=C(OH)—NH2), isothiourea (—N=C(SH)—NH2)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2086—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat
    • A61K9/209—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat containing drug in at least two layers or in the core and in at least one outer layer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
AU2001273310A 2001-07-10 2001-07-10 A core formulation Ceased AU2001273310B2 (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PCT/US2001/021676 WO2003005991A1 (en) 2001-07-10 2001-07-10 A core formulation

Publications (2)

Publication Number Publication Date
AU2001273310A1 AU2001273310A1 (en) 2003-05-22
AU2001273310B2 true AU2001273310B2 (en) 2004-10-07

Family

ID=21742691

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2001273310A Ceased AU2001273310B2 (en) 2001-07-10 2001-07-10 A core formulation

Country Status (6)

Country Link
EP (1) EP1429732A4 (ja)
JP (1) JP2004536841A (ja)
AU (1) AU2001273310B2 (ja)
CA (1) CA2453784A1 (ja)
MX (1) MXPA04000176A (ja)
WO (1) WO2003005991A1 (ja)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2453775A1 (en) * 2001-07-10 2003-01-23 Kos Life Sciences, Inc. Core formulation comprising pioglitazone hydrochloride and a biguanide
JP2004536841A (ja) * 2001-07-10 2004-12-09 エアロファーム テクノロジー インコーポレイテッド コア製剤
US7785627B2 (en) * 2002-09-20 2010-08-31 Watson Pharmaceuticals, Inc. Pharmaceutical formulation containing a biguanide and a thiazolidinedione derivative
WO2004069229A1 (en) * 2003-02-05 2004-08-19 Ipca Laboratories Limited Dual release anti-diabetic drugs and process of production thereof
WO2004091587A1 (en) * 2003-04-17 2004-10-28 Ipca Laboratories Limited Multiple release anti-diabetic drugs and process of production thereof
US20050163842A1 (en) * 2003-12-31 2005-07-28 Garth Boehm Rosiglitazone and metformin formulations
WO2010136847A1 (en) * 2009-05-26 2010-12-02 Abdi Ibrahim Ilac Sanayi Ve Ticaret Anonim Sirketi Coated metformin with pioglitazone solution

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2003005991A1 (en) * 2001-07-10 2003-01-23 Aeropharm Technology Incorporated A core formulation

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5356913A (en) * 1990-02-09 1994-10-18 The Upjohn Company Use of insulin sensitizing agents to treat hypertension
TWI238064B (en) * 1995-06-20 2005-08-21 Takeda Chemical Industries Ltd A pharmaceutical composition for prophylaxis and treatment of diabetes
US6011049A (en) * 1997-02-19 2000-01-04 Warner-Lambert Company Combinations for diabetes
US6191162B1 (en) * 1998-05-28 2001-02-20 Medical Research Institute Method of reducing serum glucose levels
US6248363B1 (en) * 1999-11-23 2001-06-19 Lipocine, Inc. Solid carriers for improved delivery of active ingredients in pharmaceutical compositions
WO2001035940A2 (en) * 1999-11-16 2001-05-25 Smithkline Beecham P.L.C. Pharmaceutical composition comprising a thiazolidinedione-metformin hydrochloride
US6780432B1 (en) * 2000-05-01 2004-08-24 Aeropharm Technology, Inc. Core formulation
CA2453775A1 (en) * 2001-07-10 2003-01-23 Kos Life Sciences, Inc. Core formulation comprising pioglitazone hydrochloride and a biguanide

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2003005991A1 (en) * 2001-07-10 2003-01-23 Aeropharm Technology Incorporated A core formulation

Also Published As

Publication number Publication date
CA2453784A1 (en) 2003-01-23
MXPA04000176A (es) 2004-10-27
WO2003005991A1 (en) 2003-01-23
EP1429732A1 (en) 2004-06-23
JP2004536841A (ja) 2004-12-09
EP1429732A4 (en) 2005-01-26

Similar Documents

Publication Publication Date Title
US6403121B1 (en) Core formulation
US6524621B2 (en) Core formulation
US6451342B2 (en) Core formulation comprised of troglitazone and a biguanide
US6780432B1 (en) Core formulation
US6296874B1 (en) Core formulation comprising troglitazone and abiguanide
CA2470581C (en) Antidiabetic formulation and method
IL158506A (en) Pharmaceutical dosage form for oral administration once daily that combines metformin and at least one other anti-diabetic active ingredient
US20060141023A1 (en) Pharmaceutical compositions containing abiguanide-glitazone combination
US6461639B2 (en) Core formulation
AU2001273310B2 (en) A core formulation
AU2001273289B2 (en) Core formulation comprising pioglitazone hydrochloride and a biguanide
AU2001273310A1 (en) A core formulation
AU2001257456B2 (en) A core formulation
AU2001273289A1 (en) Core formulation comprising pioglitazone hydrochloride and a biguanide
AU2001257456A1 (en) A core formulation
AU2001273290B2 (en) Core formulation comprising troglitazone and a biguanide
AU2001273290A1 (en) Core formulation comprising troglitazone and a biguanide

Legal Events

Date Code Title Description
PC1 Assignment before grant (sect. 113)

Owner name: KOS LIFE SCIENCES, INC.

Free format text: FORMER APPLICANT(S): AEROPHARM TECHNOLOGY, INC.

FGA Letters patent sealed or granted (standard patent)
MK14 Patent ceased section 143(a) (annual fees not paid) or expired